Europe Liquid Biopsy Market By Offering, By Technology (Polymerase Chain Reaction, Next Generation Sequencing, Others), By Application, By End User, By Country, Competition, Forecast and Opportunities, 2020-2030F

The Europe Liquid Biopsy Market was valued at USD 1.16 billion in 2024 and is expected to grow to USD 1.86 billion by 2030, at a CAGR of 11.72%. This growth is driven by increasing demand for non-invasive diagnostic techniques and the rising incidence of cancer across the region. Liquid biopsy offers a less invasive alternative to traditional tissue biopsies, providing real-time insights into tumor genetics with minimal patient discomfort. As personalized medicine gains traction, liquid biopsy is being increasingly utilized to monitor disease progression and treatment response. Advancements in circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosome-based technologies are significantly improving diagnostic sensitivity and specificity. Government and private investments in cancer research, along with the integration of artificial intelligence in data interpretation, are further propelling the market. The growing application of liquid biopsy in early cancer detection, clinical trials, and companion diagnostics is helping to shape a more patient-centric, precision oncology landscape across Europe.

Key Market Drivers

Rising Incidence of Cancer

The increasing cancer burden in Europe is a key driver fueling the adoption of liquid biopsy technologies. With around 4.47 million new cancer cases reported in 2022 and an age-standardized rate of 280 per 100,000 individuals, the need for early, accurate, and less invasive diagnostic methods is more critical than ever. Liquid biopsy enables clinicians to detect cancer-related genetic mutations and alterations using bodily fluids such as blood, allowing for real-time disease monitoring, early diagnosis, and evaluation of treatment effectiveness. This non-invasive approach reduces the need for repeated tissue biopsies and aligns with the growing trend of personalized medicine. As cancer prevalence continues to rise, particularly in countries with robust healthcare systems, liquid biopsy is increasingly being integrated into clinical workflows to support improved patient outcomes and targeted therapy decisions.

Key Market Challenges

High Cost of Liquid Biopsy Tests

The elevated cost of liquid biopsy tests remains a substantial challenge for the Europe Liquid Biopsy Market. These tests often rely on high-end technologies like next-generation sequencing (NGS), digital PCR, and complex multi-omics platforms that demand advanced lab infrastructure and skilled personnel. Comprehensive tests analyzing multiple biomarkers can be particularly expensive, limiting their affordability for many patients and straining healthcare budgets. Reimbursement policies vary across Europe, with limited or inconsistent coverage posing a barrier to broader clinical adoption. This disparity affects patient access, especially for those in early-stage diagnosis or asymptomatic phases. Consequently, even when liquid biopsy offers clear clinical benefits, its use may be restricted by economic constraints unless reimbursement frameworks evolve to support its widespread integration into standard care.

Key Market Trends

Integration of Liquid Biopsy with Companion Diagnostics

The combination of liquid biopsy and companion diagnostics is becoming a transformative trend in the Europe Liquid Biopsy Market. Companion diagnostics enable the identification of patients most likely to benefit from specific therapies by detecting relevant genetic biomarkers. When coupled with liquid biopsy, these diagnostics become more accessible, non-invasive, and practical for continuous monitoring. This approach supports the rising demand for precision oncology, allowing for tailored therapies and real-time adjustments based on the patient's evolving tumor profile. Pharmaceutical companies are increasingly collaborating with diagnostics developers to create integrated drug-diagnostic platforms, which are being utilized in both clinical trials and routine care. Regulatory support and the ability to track resistance mutations and tumor evolution further enhance the utility of these solutions. This trend is central to advancing precision medicine in Europe, improving treatment efficacy, and minimizing costs from ineffective therapies.

Key Market Players

• QIAGEN N.V.
• Epigenomics AG
• Inivata Ltd.
• Sysmex Inostics GmbH
• Stilla Technologies
• Novigenix SA
• Eurofins Genomics Europe
• Chronix Biomedical GmbH
• Genseq Ltd.
• Blueberry Therapeutics Ltd.

Report Scope:

In this report, the Europe Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Europe Liquid Biopsy Market, By Offering:

• Testing Services
• Kits
• Platform
• Other Consumables

Europe Liquid Biopsy Market, By Technology:

• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others

Europe Liquid Biopsy Market, By Application:

• Oncological
• Non-Oncological

Europe Liquid Biopsy Market, By End User:

• Clinical Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

Europe Liquid Biopsy Market, By Country:

• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Poland
• Bulgaria
• Finland
• Portugal

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Europe Liquid Biopsy Market.

Available Customizations:

Europe Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).